目的 探討小兒熱速清口服液聯(lián)合頭孢噻肟治療小兒急性上呼吸道感染的臨床療效。方法 選取2020年1月-2022年12月銅陵市婦幼保健院收治的84例急性上呼吸道感染患兒,按隨機(jī)數(shù)字表法將所有患兒分為對(duì)照組和治療組,每組各42例。對(duì)照組靜脈滴注注射用頭孢噻肟,50 mg/kg加入0.9%氯化鈉注射液100 mL中,2次/d。治療組在對(duì)照組治療基礎(chǔ)上口服小兒熱速清口服液,1 ≤ 患兒年齡<3歲者10 mL/次,3 ≤ 患兒年齡<7歲者15 mL/次,7 ≤ 患兒年齡<12歲者20 mL/次,3次/d。兩組療程均為4 d。觀察兩組解熱效果及臨床癥狀消失時(shí)間,比較治療前后兩組全血淋巴細(xì)胞與單核細(xì)胞比值(LMR)、中性粒細(xì)胞與淋巴細(xì)胞比值(NLR)、超敏C反應(yīng)蛋白(hs-CRP)水平及血清降鈣素原(PCT)水平。結(jié)果 治療后,治療組總有效率為95.24%,顯著高于對(duì)照組的80.95%(P<0.05)。治療后,治療組體溫恢復(fù)時(shí)間和解熱起效時(shí)間均顯著短于對(duì)照組,治療組即刻退熱率顯著高于對(duì)照組(P<0.05)。治療后,治療組患者鼻塞、流涕、咳嗽、咽痛的消失時(shí)間均顯著短于對(duì)照組(P<0.05)。治療后,兩組全血LMR水平均顯著上升,而全血NLR、hs-CRP和血清PCT水平均顯著下降(P<0.05);且治療后,治療組全血LMR、NLR、hs-CRP和血清PCT水平改善優(yōu)于對(duì)照組(P<0.05)。結(jié)論 小兒熱速清口服液聯(lián)合頭孢噻肟治療小兒急性上呼吸道感染具有較好的臨床療效,能有效縮短患兒癥狀體征的恢復(fù)時(shí)間,使機(jī)體炎癥狀態(tài)受到抑制,且安全性較佳,值得臨床推廣應(yīng)用。

Objective To explore the clinical efficacy of Xiaoer Resuqing Oral Liquid combined with cefotaxime in treatment of acute upper respiratory tract infection in children. Methods A total of 84 children with acute upper respiratory tract infection admitted to Tongling Maternal and Child Health Hospital from January 2020 to December 2022 were selected and divided into control group and treatment group according to random number table method, with 42 cases in each group. Patients in the control group were iv administered with Cefotaxime Sodium for injection, 50 mg/kg was added into 0.9% sodium chloride injection 100 mL, twice daily. Patients in the treatment group were po administered with Xiaoer Resuqing Oral Liquid on the basis of control group, 1 to 3 years old 10 mL/time, 3 to 7 years old 15 mL/time, 7 to 12 years old 20 mL/time, 3 times daily. The treatment course of both groups was 4 d. The antipyretic effect and the disappearance time of clinical symptoms in two groups were observed, and the levels of whole blood lymphocyte to monocyte ratio (LMR), neutrophil to lymphocyte ratio (NLR), hypersensitive C-reactive protein (hs-CRP) and serum procalcitonin (PCT) were compared before and after treatment. Results After treatment, the total effective rate of treatment group was 95.24%, which was significantly higher than that of control group (80.95%, P < 0.05). After treatment, the temperature recovery time and antipyretic onset time of treatment group were significantly shorter than those of control group, and the immediate antipyretic rate of treatment group was significantly higher than that of control group (P < 0.05). After treatment, >the disappearance time of nasal congestion, runny nose, cough and sore throat in treatment group was significantly shorter than that in control group (P < 0.05). After treatment, whole blood LMR levels were significantly increased in both groups, but whole blood NLR, hs-CRP and serum PCT levels were significantly decreased (P < 0.05). After treatment, whole blood LMR, NLR, hs-CRP and serum PCT levels in treatment group were better than those in control group (P < 0.05). Conclusion Xiaoer Resuqing Oral Liquid combined with cefotaxime has good clinical efficacy in treatment of acute upper respiratory tract infection in children, and can effectively shorten the recovery time of symptoms and signs in children, inhibit the inflammatory state of the body with good safety, which is worthy of clinical application.

R974

安徽省衛(wèi)生健康科研項(xiàng)目（AHWJ2022c059）